Cargando…
Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658122/ https://www.ncbi.nlm.nih.gov/pubmed/33209701 http://dx.doi.org/10.21037/tau-20-876 |
| _version_ | 1783608599028695040 |
|---|---|
| author | Scandura, Carmen Morgia, Giuseppe Russo, Giorgio Ivan |
| author_facet | Scandura, Carmen Morgia, Giuseppe Russo, Giorgio Ivan |
| author_sort | Scandura, Carmen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7658122 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76581222020-11-17 Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo Scandura, Carmen Morgia, Giuseppe Russo, Giorgio Ivan Transl Androl Urol Editorial Commentary AME Publishing Company 2020-10 /pmc/articles/PMC7658122/ /pubmed/33209701 http://dx.doi.org/10.21037/tau-20-876 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Scandura, Carmen Morgia, Giuseppe Russo, Giorgio Ivan Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| title | Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| title_full | Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| title_fullStr | Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| title_full_unstemmed | Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| title_short | Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| title_sort | comment on: safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658122/ https://www.ncbi.nlm.nih.gov/pubmed/33209701 http://dx.doi.org/10.21037/tau-20-876 |
| work_keys_str_mv | AT scanduracarmen commentonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo AT morgiagiuseppe commentonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo AT russogiorgioivan commentonsafetyandefficacyofmirabegronanalysisofalargeintegratedclinicaltrialdatabaseofpatientswithoveractivebladderreceivingmirabegronantimuscarinicsorplacebo |